Log In
Print
BCIQ
Print
Print this Print this
 

Aloxi, Onicit, Paloxi, palonosetron

  Manage Alerts
Collapse Summary General Information
Company Helsinn Healthcare S.A.
DescriptionSelective serotonin (5-HT3) receptor antagonist
Molecular Target Serotonin (5-HT3) receptor
Mechanism of ActionSerotonin (5-HT3) receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationEmesis
Indication DetailsPrevent acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy in patients ages 1 month to <17 years; Prevent chemotherapy-induced nausea and vomiting (CINV); Prevent chemotherapy-induced nausea and vomiting (CINV) in pediatric patients; Prevent post-operative nausea and vomiting (PONV); Treat chemotherapy-induced nausea and vomiting (CINV)
Regulatory Designation U.S. - Undisclosed Review (Prevent chemotherapy-induced nausea and vomiting (CINV) in pediatric patients)
Partner Eisai Co. Ltd.; Lee's Pharmaceutical Holdings Ltd.; Taiho Pharmaceutical Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

6

$8.9M

$3.8M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today